Aboutzenlife
Home » Pros and Cons of GLP-1 Drugs

Pros and Cons of GLP-1 Drugs

GLP-1 drugs like semaglutide (Ozempic, Wegovy) lower blood sugar and appetite by mimicking a gut hormone. In the SELECT trial, semaglutide cut heart attacks, strokes and cardiovascular deaths by 20% in adults with heart disease and excess weight. The costs: common stomach side effects, a boxed thyroid-tumor warning, a small rise in pancreatitis risk, and weight regain after stopping.

Updated November 9, 2026.

Have you heard of GLP-1 therapy? Drugs like Ozempic and Wegovy started out in diabetes clinics and now seem to be in every other news story. Under the weight-loss hype there is a lot of nuance. GLP-1 drugs can help with blood sugar and weight, but they also bring side effects, a real cost and open questions about the long term. For patients and doctors alike, the stakes are real. I’ve followed the GLP-1 research closely since these drugs jumped from clinics to the evening news. The question I hear most is a plain one: is it worth it? The trials give a mixed answer. There is a real heart benefit and a real stomach cost. The long-term safety picture is still filling in as more people stay on these drugs for years. Most of us have read a big claim online and wondered what the fine print says. This post is the fine print.

What GLP-1 therapy does in the body

GLP-1 receptor agonists copy glucagon-like peptide-1, a hormone the gut releases after eating. MedlinePlus is the National Library of Medicine’s drug reference. It says semaglutide helps the pancreas release the right amount of insulin when blood sugar is high. It also slows how fast the stomach empties, which can lower appetite. That slower stomach is why nausea, vomiting, diarrhea, stomach pain, constipation and heartburn are on MedlinePlus’s list of common side effects.

The pro: a real drop in heart attack and stroke risk

The strongest evidence for GLP-1 drugs is about the heart. The SELECT trial was published in the New England Journal of Medicine. It randomly assigned 17,604 adults to semaglutide or placebo. All of them had existing cardiovascular disease and overweight or obesity, but no diabetes. Over a mean follow-up of 39.8 months, cardiovascular death, nonfatal heart attack or nonfatal stroke happened in 6.5% of the semaglutide group and 8.0% of the placebo group. That is a hazard ratio of 0.80, or a 20% lower risk. On March 8, 2024, the FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack and stroke. The approval is for adults with cardiovascular disease and either obesity or overweight.

The con: gastrointestinal side effects are common

Nausea, vomiting, diarrhea and constipation are listed by MedlinePlus as common side effects of semaglutide. They come from how the drug works: food leaves the stomach more slowly, which brings the fullness and also the discomfort. MedlinePlus says your doctor will probably start you on a low dose and raise it after 4 weeks. In SELECT, 16.6% of people on semaglutide stopped the drug for good because of adverse events, against 8.2% on placebo.

The con: a small rise in pancreatitis risk

A 2025 systematic review and meta-analysis in Endocrinology, Diabetes & Metabolism pooled 62 randomized controlled trials. They covered 66,232 patients. It found that GLP-1 receptor agonists carried a relative risk of 1.44 for pancreatitis compared with placebo, about 44% higher. The authors call it a slightly increased risk. The same review found no significant overall increase in pancreatic cancer. MedlinePlus asks you to tell your doctor if you have ever had pancreatitis. It also lists a serious side effect: ongoing pain that starts in the upper left or middle of the stomach. The pain may spread to the back, with or without vomiting.

The con: a boxed warning on thyroid tumors

If you’ve ever read the folded paper that comes with a prescription, you know the warnings can run long, and it’s easy to skim them. This one is worth reading. Semaglutide carries a boxed warning, the FDA’s most serious kind, because it caused thyroid tumors in rats. MedlinePlus says it is not known whether the drug raises tumor risk in humans. Tell your doctor if you or anyone in your family has had thyroid tumors, thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN 2). MedlinePlus lists a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath as symptoms to report.

The con: GLP-1 therapy cost and the rebound after stopping

The appetite effect lasts only as long as the drug does. A 2026 meta-analysis in eClinicalMedicine, reported by the University of Cambridge, found people regained an average of 60% of the weight they had lost within 52 weeks of stopping. Hormones drive that. It shows why it is hard to lose weight and keep it off. It also means the cost is ongoing for most people who start. Most of us have signed up for something and then looked twice at the monthly bill. For many people the choice comes down to weighing the hope of better health against a cost that keeps coming. Coverage for weight-loss use depends on your plan, so ask your insurer before the first fill.

None of this rules GLP-1 drugs out. It means you walk into the conversation with your doctor knowing both sides. Anyone who has sat in a waiting room with a list of questions knows how fast the visit goes by, so write yours down first. The FDA approval pairs Wegovy with a reduced-calorie diet and more physical activity, and these tips on maintaining weight loss goals cover the daily side of that. If a smaller appetite leaves you eating less overall, make the food you do eat count; the healthiest fruits to add to your diet are an easy place to start.

GLP-1 therapy: FAQ

Are GLP-1 drugs safe for the heart?

The SELECT trial followed 17,604 adults with heart disease and overweight or obesity, without diabetes. Semaglutide lowered the combined rate of cardiovascular death, heart attack and stroke by 20% compared with placebo. On that evidence, the FDA approved Wegovy in March 2024 to reduce those risks, separate from its weight-loss approval.

Do GLP-1 drugs cause pancreatitis?

A 2025 meta-analysis of 62 randomized trials found a 44% higher relative risk of pancreatitis with GLP-1 drugs compared with placebo, which the authors describe as a slight increase. It found no significant overall rise in pancreatic cancer. Anyone who has had pancreatitis should tell their prescriber before starting.

What is the thyroid tumor warning about?

Semaglutide caused thyroid tumors in rats, which led to the FDA’s boxed warning. Whether the same risk applies to humans is not known. People with a personal or family history of thyroid tumors, thyroid cancer or MEN 2 should tell their doctor before using it.

What happens if I stop GLP-1 therapy?

The appetite and fullness effects fade once the drug is gone, and hunger tends to come back. A 2026 meta-analysis in eClinicalMedicine found people regained an average of 60% of the weight they had lost within a year of stopping. Talk to your prescriber before you stop or change any dose.

MEDICAL DISCLAIMER: We are not doctors or medical professionals, and nothing in this article is medical advice. This content is for general informational purposes only. GLP-1 medications are prescription drugs that require evaluation by a licensed healthcare provider, and they are not appropriate for everyone. Always consult a qualified healthcare provider before starting, stopping, or changing any medication, diet, or exercise program.

AFFILIATE DISCLOSURE: Some links on our site may earn us a commission at no extra cost to you. Commissions never influence our editorial content. See our Affiliate Disclosure page for details.

This article is for general information only and is not medical advice. Talk to your doctor or another qualified health professional before changing your diet, exercise, supplements or medication. Read our medical disclaimer.
Disclaimer This content is for informational purposes only and does not constitute medical advice, specific dietary guidelines, or exercise recommendations. This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Individual needs vary. Always consult a qualified healthcare provider before making changes to your health, diet, or lifestyle.